Edition:
United Kingdom

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

1.69USD
19 Oct 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.69
Open
$1.75
Day's High
$1.76
Day's Low
$1.69
Volume
25,925
Avg. Vol
38,584
52-wk High
$4.56
52-wk Low
$1.65

Latest Key Developments (Source: Significant Developments)

Nymox Announces Relocation Of Company Headquarters To Switzerland
Monday, 7 May 2018 

Nymox Pharmaceutical Corp ::NYMOX ANNOUNCES RELOCATION OF COMPANY HEADQUARTERS TO SWITZERLAND.NYMOX PHARMACEUTICAL CORP - INITIATED PROCESS OF RELOCATING COMPANY HEADQUARTERS FROM NASSAU, BAHAMAS TO ZUG IN SWITZERLAND.NYMOX PHARMACEUTICAL CORP - PREPARING FOR SCALE-UP & COMMERCIALIZATION FOR FEXAPOTIDE TRIFLUTATE AS A COMPLETELY NEW TREATMENT OPTION.NYMOX PHARMACEUTICAL - COMMERCIALIZATION FOR FEXAPOTIDE TRIFLUTATE FOR MEN SUFFERING FROM PROSTATE PROBLEMS ASSOCIATED WITH AGING & PROSTATE ENLARGEMENT.NYMOX PHARMACEUTICAL CORP - EXPECTS TO REPORT ON EUROPEAN REGULATORY REVIEW PROCESS BY END OF Q3 2018.  Full Article

Nymox Announces $16.25 Million Equity Financing
Thursday, 12 Apr 2018 

April 12 (Reuters) - Nymox Pharmaceutical Corp ::NYMOX ANNOUNCES $16.25 MILLION EQUITY FINANCING WITH QUALIFIED LONG-TERM INVESTORS.WITH NEW FUNDS, TO BE FINANCED BEYOND EXPECTED OUTCOME TIMINGS FOR REGULATORY SUBMISSIONS IN EUROPE & U.S. FOR FEXAPOTIDE TRIFLUTATE.  Full Article

Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Nymox Pharmaceutical Corp ::NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN.NYMOX - HIGH DOSE FEXAPOTIDE 15MG SINGLE DOSAGE TREATMENT RESULTED IN 80% LESS SURGERY OR RADIOTHERAPY ASSOCIATED WITH GLEASON GRADE PROGRESSION.NYMOX PHARMACEUTICAL CORP - STUDY ALSO SHOWED THAT BOTH DOSES OF FEXAPOTIDE WERE CONSISTENTLY EFFECTIVE.  Full Article

Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing‍​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Nymox Pharmaceutical Corp :Nymox Pharmaceutical Corp qtrly loss per share $0.09 - SEC filing‍​.  Full Article

Nymox Pharmaceutical says ‍European member states accepted MAA​ for fexapotide triflutate
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Nymox Pharmaceutical Corp :Says ‍European member states for Nymox's MAA for fexapotide triflutate for treatment of benign prostatic hyperplasia accepted co's MAA​.  Full Article